Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC. Antipsychotics, Other Psychotropics, and the Risk of Death in Patients With DementiaNumber Needed to Harm. JAMA Psychiatry. 2015;72(5):438–445. doi:10.1001/jamapsychiatry.2014.3018
Antipsychotic medications are associated with increased mortality in older adults with dementia, yet their absolute effect on risk relative to no treatment or an alternative psychotropic is unclear.
To determine the absolute mortality risk increase and number needed to harm (NNH) (ie, number of patients who receive treatment that would be associated with 1 death) of antipsychotic, valproic acid and its derivatives, and antidepressant use in patients with dementia relative to either no treatment or antidepressant treatment.
Design, Setting, and Participants
A retrospective case-control study was conducted in the Veterans Health Administration from October 1, 1998, through September 30, 2009. Participants included 90 786 patients 65 years or older with a diagnosis of dementia. Final analyses were conducted in August 2014.
A new prescription for an antipsychotic (haloperidol, olanzapine, quetiapine, and risperidone), valproic acid and its derivatives, or an antidepressant (46 008 medication users).
Main Outcomes and Measures
Absolute change in mortality risk and NNH over 180 days of follow-up in medication users compared with nonmedication users matched on several risk factors. Among patients in whom a treatment with medication was initiated, mortality risk associated with each agent was also compared using the antidepressant group as the reference, adjusting for age, sex, years with dementia, presence of delirium, and other clinical and demographic characteristics. Secondary analyses compared dose-adjusted absolute change in mortality risk for olanzapine, quetiapine, and risperidone.
Compared with respective matched nonusers, individuals receiving haloperidol had an increased mortality risk of 3.8% (95% CI, 1.0%-6.6%; P < .01) with an NNH of 26 (95% CI, 15-99); followed by risperidone, 3.7% (95% CI, 2.2%-5.3%; P < .01) with an NNH of 27 (95% CI, 19-46); olanzapine, 2.5% (95% CI, 0.3%-4.7%; P = .02) with an NNH of 40 (95% CI, 21-312); and quetiapine, 2.0% (95% CI, 0.7%-3.3%; P < .01) with an NNH of 50 (95% CI, 30-150). Compared with antidepressant users, mortality risk ranged from 12.3% (95% CI, 8.6%-16.0%; P < .01) with an NNH of 8 (95% CI, 6-12) for haloperidol users to 3.2% (95% CI, 1.6%-4.9%; P < .01) with an NNH of 31 (95% CI, 21-62) for quetiapine users. As a group, the atypical antipsychotics (olanzapine, quetiapine, and risperidone) showed a dose-response increase in mortality risk, with 3.5% greater mortality (95% CI, 0.5%-6.5%; P = .02) in the high-dose subgroup relative to the low-dose group. When compared directly with quetiapine, dose-adjusted mortality risk was increased with both risperidone (1.7%; 95% CI, 0.6%-2.8%; P = .003) and olanzapine (1.5%; 95% CI, 0.02%-3.0%; P = .047).
Conclusions and Relevance
The absolute effect of antipsychotics on mortality in elderly patients with dementia may be higher than previously reported and increases with dose.
Individual clinical trials and meta-analyses have suggested modest benefit from some antipsychotic agents over placebo for the treatment of psychosis and aggression in patients with dementia1- 3 and that these symptoms may return when a medication is discontinued.4 Potential harms anticipated with use of these medications include known adverse effects such as metabolic changes and extrapyramidal symptoms.1,5,6 However, evidence pooled across randomized, placebo-controlled trials (RCTs) of atypical antipsychotics, such as risperidone and olanzapine, demonstrated an increased risk of cerebrovascular adverse events for which the US Food and Drug Administration (FDA) issued a warning in 2003.7 Subsequent analyses of published and unpublished clinical trial data on atypical antipsychotics by the FDA and a meta-analysis of 15 RCTs by Schneider et al8 demonstrated an increased mortality risk. In April 2005, the FDA9 issued a black box warning that the use of atypical antipsychotics leads to increased all-cause mortality when used for behavioral disturbances in patients with dementia. Additional observational analyses10,11 have demonstrated that first-generation antipsychotic agents confer an even higher mortality risk than do the atypical agents, leading to another FDA12 black box warning in 2008. However, at the time the warnings were issued, the available evidence described class-wide effects on mortality without clear delineation of the risks associated with individual medications.
Using a large national registry of Veterans Affairs (VA) patients with dementia, Kales et al13 published the first analyses that provided estimates of the head-to-head mortality risk over 180 days, comparing individual antipsychotic agents and valproic acid and its derivatives (hereafter referred to as valproic acid), which are frequently used alternatives14 for behavioral disturbances in dementia. Subsequent analyses of elderly community-dwelling15 and nursing home16 patients have generally confirmed the initial findings that individual antipsychotic agents vary in their mortality risk, ranging from quetiapine (lowest) to haloperidol (highest).
The decision to use any intervention in medicine requires balancing potential benefits with potential harms, but it can be difficult for clinicians to interpret the clinical significance of absolute changes in risk or benefit. The number needed to harm (NNH) is a useful metric for clinicians to understand a treatment’s potential for harm, expressing the number of patients who have to receive treatment for a particular harmful outcome to occur with the intervention.17 The NNH is formally defined as the reciprocal of the change in absolute risk. Two sets of meta-analyses of atypical RCTs by Schneider et al1,8 provided key preliminary evidence for clinicians to help weigh the relative benefits and risks of using antipsychotics. First, this group demonstrated the increased mortality risk of atypical antipsychotics relative to placebo in patients with dementia,8 showing an absolute mortality risk increase of 1% over 8 to 12 weeks of treatment, or an NNH of 100 (1/.01). The authors suggested that this degree of risk may be similar to that of other types of medications used in frail, elderly patients, although subsequent work18 has demonstrated that the mortality risk associated with antipsychotic treatment is greater than that with other psychotropic medications. In a second set of analyses, Schneider et al1 examined the potential benefits of treatment with antipsychotics. Depending on the outcome measure and criterion for improvement, the number needed to treat ranged from 5 to 14, in contrast to the NNH of 100.
Over the past several years, investigators have consistently demonstrated both class- and agent-specific associations with increased mortality risk when these agents are used to treat dementia-related behavioral disturbances. However, when faced with the clinical decision of whether to prescribe a given medication for a given patient, physicians may have difficulty quantifying and comparing the risk. Here, we build on previous observational analyses of a cohort of patients with dementia newly treated with an antipsychotic (haloperidol, olanzapine, quetiapine, and risperidone) to estimate the increased absolute mortality risk and corresponding NNH during 180 days of follow-up relative to no treatment. Similar analyses are included for valproic acid and antidepressants since they are commonly used as alternatives to antipsychotics for aggression/agitation in dementia.14 Then, given the interest in antidepressant agents as more benign alternatives to antipsychotics19,20 and their increased use following the FDA warnings,14 we describe the mortality risk and NNH of antipsychotics and valproic acid relative to antidepressants. Finally, we provide estimates of the increased risk across atypical antipsychotics by agent and by dose.
The data source and characteristics used here are similar to those previously published.13 In brief, deidentified data were provided by national VA registries maintained by the Serious Mental Illness Treatment Resource and Evaluation Center in Ann Arbor, Michigan, and the study was approved, with waiver of informed consent, by the VA Ann Arbor Healthcare System. Patients potentially included were aged 65 years or older and had a dementia diagnosis for at least 1 inpatient or outpatient encounter (International Classification of Diseases, Ninth Revision [ICD-9] codes 290.0, 290.1x, 290.2x, 290.3, 290.4x, 291.2, 294.10, 294.11, 331.0, 331.1, and 331.82) between October 1, 1998, and September 30, 2009. The cohort was then limited to patients who began outpatient treatment with a study medication following a period of at least 6 months without exposure to any antipsychotic, antidepressant, or anticonvulsant. Based on previous work demonstrating that 87% of VA patients with dementia received antipsychotic monotherapy,13 we limited this cohort to monotherapy. In the event that patients had more than 1 treatment episode during the 11-year study period, the first episode was used. The final treatment group included 46 008 medication users.
We included the antipsychotics haloperidol, olanzapine, risperidone, and quetiapine; the anticonvulsant valproic acid and its derivatives; and antidepressants, excluding tricyclic antidepressants or monoamine oxidase inhibitors. Patients taking valproic acid who had a diagnosis of a seizure disorder were excluded from the sample.
The primary study outcome was 180-day mortality, with mortality data obtained from the US National Death Index (National Center for Health Statistics).21 Secondary analyses compared dose-adjusted absolute change in mortality risk for olanzapine, quetiapine, and risperidone.
Variables included sex, age, race, marital status, active clinical diagnoses, and prescriptions for benzodiazepines and opioids during the 12 months before the index date when treatment began. Time since dementia diagnosis was used as a proxy for dementia severity. Because antipsychotics are frequently prescribed for treatment of delirium, and delirium itself is a risk factor for mortality, we used a coding scheme for acute confusional states developed for a previous study22 to capture the presence of delirium. This scheme included the following ICD-9 codes: 290.3, 291.0, 292.0, 292.1, 292.2, 292.9, 293.0, 293.1, 293.9, 294.8, 294.9, 348.3, 437.2, 572.2, 290.11, 290.41, 292.81, 293.31, 293.82, 293.83, 293.89, and 349.82. A Charlson Comorbidity Index score23 was calculated based on the presence of 18 medical comorbidities (excluding dementia) and then categorized as 0, 1, and greater than 1. We also included days in the hospital and in the nursing home during the 12 months before the index date, as well as urban vs rural location, academic affiliation, and size of the treating facility. The fiscal year of the prescription was also included as a variable to account for secular trends in the use of these medications.14,24
Once the medication-user cohort was defined, to estimate the increased mortality risk difference and corresponding NNH relative to no treatment, we paired each medication user with a matching nonuser patient. First, we created a nonuser cohort of patients potentially eligible for matching: these individuals were aged 65 years or older, had a diagnosis of dementia (as described above), and had at least 6 months free of any antipsychotic, antidepressant, and anticonvulsant. For each medication-using patient, potential matching nonuser patients were first identified matching on the calendar year of the initial dementia diagnosis. Next, potential matching nonuser patients had a phantom fill date created that was the same number of days from the dementia diagnosis as for the corresponding medication-using patient. Using this phantom fill date, each medication-using patient was paired to an eligible nonuser patient selected randomly from the matching nonuser pool, and was matched further on additional patient characteristics at that time including age (±2.5 years), race, delirium diagnosis within the preceding 12 months, psychiatric hospitalization within the preceding 12 months, and 3-category Charlson Comorbidity Index score. Because medication users were limited to monotherapy, a potential nonuser was excluded if treatment with any antidepressant, antipsychotic, or anticonvulsant medication was started during the 180-day observation period.
The final study monotherapy cohort included 46 008 users; for the matched cohort, 45 393 of the monotherapy users were matched with nonusers. Descriptive statistics captured patient characteristics by medication prescribed (Table 1). A 180-day observation period was chosen based on previously published analyses.10,11,13 The outcome was death within the observation period following a new prescription (or phantom fill date for the nonuser cohort).
Two primary analyses were done. First, we estimated the mortality risk difference for each medication relative to no treatment based on matched user and nonuser patients for each agent. We used a generalized linear model with logit link to fit a logistic regression model for the 180-day mortality risk associated with a given medication. We accounted for pairing between medication user and matched nonuser using a generalized estimating equation and adjusted for other clinical and demographic variables available in the administrative data (Table 2 footnote provides full list of covariates). Based on this model, we calculated the absolute difference in mortality risk and the corresponding NNH for patients in each medication group relative to each matched nonuser cohort. Next, to estimate the 180-day mortality risk difference and NNH for each medication compared with antidepressants, we used a logistic regression model with data from the full monotherapy cohort. Primary predictors in the model were dummy indicators for each study medication, with antidepressants as the referent medication group.
As a secondary analysis, we compared the mortality risk difference across the 3 atypical antipsychotics (olanzapine, quetiapine, and risperidone) controlling for medication dosage. Among these patients, 14.7% (n = 1929) had missing dosage data; thus, missing dosages were multiply imputed using a multivariate normal model that included all covariates and study medications as well as mortality. Imputation was done using SAS, version 9.3 (SAS Institute Inc). Given evidence suggesting that mortality is associated with medication dosage,15 we first grouped the 3 atypical antipsychotic users by haloperidol-equivalent dosage25 (low [<1.5 mg/d], medium [1.5 to <3.0 mg/d], and high [≥3.0 mg/d]) to calculate dose-based absolute mortality risk differences, using the low-dose group as the reference. Lastly, mortality risk differences were calculated for olanzapine and risperidone relative to quetiapine, adjusting for haloperidol-equivalent prescribed dose and clinical and demographic variables. The risk difference estimates were pooled across 5 multiply-imputed data sets with the Rubin method26 and were used to calculate the risk of death and NNH. As a sensitivity analysis, comparisons among the atypical antipsychotics by medication and by haloperidol-equivalent dosage were done only among medication users with valid dose information.
Table 1 presents the clinical and demographic characteristics of the study population stratified by medication group. Patients who were receiving haloperidol were significantly sicker than were those in the other medication groups, with a generally higher Charlson Comorbidity Index score, more days of hospitalization, and more nursing home days. This group was more likely to have received a delirium diagnosis within the prior 12 months and had the largest proportion also receiving benzodiazepines. The haloperidol group had a higher proportion of African American patients and a lower proportion of married patients than did the other medication groups. In addition, relative to the other groups, a larger proportion of patients receiving haloperidol were in facilities with fewer beds.
The valproic acid and antidepressant groups had the lowest proportions of African American patients, and the antidepressant group had the smallest proportion of patients who had received a benzodiazepine or a diagnosis of delirium within the prior 12 months. The antidepressant group had the highest proportion of patients with a comorbid diagnosis of depression, posttraumatic stress disorder, and other anxiety disorders; the valproic acid group included the highest proportion of patients with a comorbid bipolar disorder diagnosis. The olanzapine group had the smallest proportion of patients with a Charlson Comorbidity Index score greater than 1. Although the antidepressant group was second only to the haloperidol group for share of patients with Charlson Comorbidity Index score greater than 1, the antidepressant group had the largest proportions of patients with no hospital or nursing home days in the year before the index.
Table 2 presents the 180-day crude mortality for medication users and their matched nonuser counterparts. Haloperidol users had the highest mortality (20.7%) relative to nonusers, followed by risperidone (13.9%), olanzapine (13.9%), valproic acid (12.2%), quetiapine (11.8%), and antidepressants (8.3%). The crude mortality rates among matched nonusers ranged from 9.8% (matched nonusers for olanzapine) to 7.2% (matched nonusers for valproic acid).
The adjusted absolute mortality risk difference between medication users and matched nonusers is also presented in Table 2. The adjusted mortality risk was higher for haloperidol users relative to matched nonusers by 3.8% (95% CI, 1.0%-6.6%; P < .01). In terms of NNH, treatment with haloperidol was associated with 1 death for every 26 (1/.038; 95% CI, 15-99) patients who received treatment. Among the other antipsychotics, quetiapine had the lowest association with mortality relative to matched nonusers, with an adjusted risk difference of 2.0% (95% CI, 0.7%-3.3%; P < .01; NNH, 50; 95% CI, CI 30-150). The antidepressant group had only a slightly increased risk of death relative to matched nonusers; the risk difference for valproic acid and its derivatives was not significantly different from 0, providing no clear evidence for increased mortality. Including rurality and facility size as covariates did not impact the results.
Table 3 presents the adjusted mortality risk directly comparing the study psychotropic medications, using antidepressants as the reference group. Relative to other psychotropic monotherapy agents, haloperidol was associated with the greatest mortality risk, with an absolute risk of 12.3% higher (95% CI, 8.6%-16.0%; P < .01) than antidepressants, yielding an NNH of 8 (95% CI, 6-12) compared with antidepressant treatment. Quetiapine use had the lowest effect on mortality, with a 3.2% (95% CI, 1.6%-4.9%; P < .01) higher mortality risk relative to antidepressants (NNH, 31; 95% CI, 21-62).
Dosage information for olanzapine, quetiapine, and risperidone is presented in Table 4. Compared with the low-dose haloperidol-equivalent group, mortality for the medium-dose group was nonsignificantly higher (1.3%; 95% CI, −0.1% to 2.7%; P = .07), but the high-dose group had significantly increased mortality (3.5%; 95% CI, 0.5% to 6.5%; P = .02; NNH, 29; 95% CI, 15-200). Controlling for dose, the 3 second-generation antipsychotics differed in mortality risk when compared directly. Relative to quetiapine, olanzapine increased the risk by 1.5% (95% CI, 0.02% to 3.0%; P = .047; NNH, 67; 95% CI, 33 to 5000) and risperidone increased the risk by 1.7% (0.6% to 2.8%, P = .003; NNH, 59; 95% CI, 36 to 167). Sensitivity analyses evaluating only medication users with valid dose information also demonstrated increased mortality risk among the high-dose group and the risperidone group. However, the increased risk associated with olanzapine relative to quetiapine was no longer statistically significant.
Building on previous work in this large national sample of outpatients with dementia, we examined the mortality risk associated with newly prescribed antipsychotics, valproic acid, and antidepressants. Compared with the matched cohort of medication nonusers, the mortality risk associated with haloperidol was the highest overall among the study medications, and risperidone was the highest among the atypical antipsychotics. Antidepressant use was associated with a small, but statistically significant, increase in mortality. This finding is of note in light of the recent RCT20 suggesting that citalopram significantly reduced agitation but may also carry adverse cognitive and cardiac effects. Our findings suggest that, during a 180-day period, starting haloperidol therapy for a patient with dementia may be associated with 1 additional death for every 26 patients receiving treatment. For the atypical antipsychotics, the NNH ranged from 27 to 50 relative to the NNH in matched nonusers. When directly comparing other medication users with patients receiving antidepressants, haloperidol had the largest associated mortality risk and quetiapine had the least risk. Comparing the atypical antipsychotics directly and controlling for dose, both risperidone and olanzapine increased mortality relative to quetiapine, although the increased risk with olanzapine was no longer significant in the sensitivity analysis limited to nonimputed data. Lastly, the analyses suggested a dose-response relationship between atypical antipsychotics and risk of mortality.
The increased risk of mortality is higher than that previously reported, although prior estimates were from RCTs, which are less subject to confounding by indication. In 2005, Schneider et al8 originally reported an NNH for death of 100 for the second-generation agents from clinical trials of 10 to 12 weeks. A more recent Agency for Healthcare Research and Quality Comparative Effectiveness Review found a slightly lower NNH for a mortality of 87 for patients with dementia.27 The results of the present study confirm previous findings that have demonstrated that haloperidol has the highest associated mortality risk, followed by atypical antipsychotics and valproic acid.10,13,15,16,18 Even quetiapine, which was consistently found to be less harmful than other antipsychotics, had an increased mortality risk of 2.0% (95% CI, 0.7-3.3; P < .01) relative to matched nonusers, yielding an NNH of 50 (95% CI, 30-150). Although quetiapine appears to have the least association with mortality, it also has less evidence of benefit than olanzapine or risperidone.1,3
Our findings suggest that the mortality risk for the least harmful antipsychotic studied (quetiapine) is double that of the initial estimate of Schneider et al8; for risperidone the mortality risk is nearly 4-fold higher. In addition, our secondary analyses demonstrated a mortality dose response, suggesting that a strategy using a high dose rather than a low dose (eg, risperidone, 3.0 mg rather than 0.5 mg) may be associated with additional mortality. Although the prior estimates were based on RCTs completed during 6 to 12 weeks,3,8 the longer period of analysis in the present study is likely a more accurate reflection of how these medications are used in the community and therefore may more fully capture the association with mortality.
The primary limitations of this study stem from the use of an administrative, claims-based database lacking information on dementia severity and behavioral or psychiatric symptoms. Although the analyses were adjusted for a wide range of clinical characteristics, the clinical complexity of these patients, who were not randomly assigned to treatment, may not have been captured. Some analyses28- 30 have found an association between certain neuropsychiatric symptoms and mortality, so it is conceivable that a portion of the increased mortality risk seen in medication users relative to nonusers or among the medication users could be related to the symptom or behavior that prompted the prescription. In addition, our analyses were limited to episodes of medication monotherapy during the first treatment episode, which potentially limits the generalizability.
The balance of benefit to risk of antipsychotic treatment in dementia continues to shift, as our findings suggest that use of these medications may be associated with increased mortality of a greater magnitude than previously described. The present analyses provide critical information that can help physicians minimize potential harms at multiple decision points. If an antipsychotic or alternative psychotropic is prescribed, how much may this increase the patient’s risk of mortality? If a second-generation antipsychotic is prescribed, which agent is most associated with increased mortality? Is dose of an antipsychotic associated with mortality? The decision to use these medications is generally in response to profoundly distressing and potentially dangerous behaviors of patients. Prescribing a medication that increases mortality risk seems contrary to the tenet “first, do no harm,” yet for patients who pose a danger to themselves and others and are in profound distress, use of such medications may still be appropriate.31,32 These new data can help physicians minimize the potential harm associated with antipsychotic treatment.
Submitted for Publication: April 7, 2014; final revision received August 25, 2014; accepted November 8, 2014.
Corresponding Author: Donovan T. Maust, MD, MS, Department of Psychiatry, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd, Bldg 16, Room 217W, Ann Arbor, MI 48109 (email@example.com).
Published Online: March 18, 2015. doi:10.1001/jamapsychiatry.2014.3018.
Author Contributions: Dr Kales had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Kim, Seyfried, Schneider, Kales.
Acquisition, analysis, or interpretation of data: Maust, Kim, Chiang, Kavanagh, Kales.
Drafting of the manuscript: Maust, Kales.
Critical revision of the manuscript for important intellectual content: Maust, Kim, Seyfried, Chiang, Kavanagh, Schneider, Kales.
Statistical analysis: Kim, Chiang.
Obtained funding: Kim, Kavanagh, Kales.
Administrative, technical, or material support: Seyfried, Kavanagh, Kales.
Study supervision: Schneider, Kales.
Conflict of Interest Disclosures: Dr Schneider has received grants from the National Institute on Aging, the State of California, the Alzheimer’s Association, and grants or research support from Johnson & Johnson, Eli Lilly, Novartis, and Pfizer. He has served as a consultant for and received consulting fees from Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Johnson & Johnson, Lundbeck, Merck, Novartis, Pfizer, Takeda, and the State of California Department of Justice. Dr Kim has received grants from the National Institute of Mental Health, National Institute of Nursing Research, and the Department of Veterans Affairs. In addition to the funding noted above, Dr Kales reports receipt of grants from the National Institute of Nursing Research and the Department of Veterans Affairs. No other disclosures are reported.
Funding/Support: This work was supported by National Institute of Mental Health grant R01MH08107-01 and the Beeson Career Development Award Program (K08AG048321; funded through the National Institute on Aging, the American Federation for Aging Research, The John A. Hartford Foundation, and The Atlantic Philanthropies; Dr Maust, principal investigator).
Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.